论文部分内容阅读
目的观察扶正化瘀胶囊联合干扰素及利巴韦林治疗慢性丙型肝炎患者抗纤维化的疗效。方法选取32例慢性丙型肝炎患者,随机分为治疗组(扶正化瘀胶囊+干扰素及利巴韦林)和对照组(干扰素和利巴韦林)。观察治疗前、治疗12周、治疗24周、治疗48周时,观察两组患者的肝功能、HCV-RNA、肝纤维化指标。结果治疗致48周时两组患者在HCV-RNA的阴转率和ALT的复常率比较无明显的差异(P>0.05)。但两组患者在肝纤维化指标的改善上有明显的差异(P<0.05)。两组患者在治疗的过程中未见明显的不良反应。结论扶正化瘀有良好的抗纤维化作用。
Objective To observe the therapeutic effects of Fuzhenghuayu Capsule combined with interferon and ribavirin in the treatment of chronic hepatitis C patients with anti-fibrosis. Methods 32 patients with chronic hepatitis C were randomly divided into treatment group (Fuzhenghuayu capsule + interferon and ribavirin) and control group (interferon and ribavirin). Before treatment, 12 weeks of treatment, 24 weeks of treatment, 48 weeks of treatment, the liver function, HCV-RNA and liver fibrosis indexes of the two groups were observed. Results There was no significant difference in the rate of negative conversion of HCV-RNA between the two groups after 48 weeks of treatment (P> 0.05). However, there was a significant difference between the two groups in improving the indexes of liver fibrosis (P <0.05). Two groups of patients in the course of treatment showed no significant adverse reactions. Conclusions Fuzhenghuayu has a good anti-fibrosis effect.